ACTIVE

DR MUYLLE-NUCLEAIRE GENEESKUNDE & DR REYNDERS -KLINISCHE BIOLOGIE

Financial year 2024 · Closed on 31/12/2024

Net result192,2 k €+7,9 %over 1 year

Gross margin401 k €+16,8 %over 1 year

Equity1 M €+23,2 %over 1 year

Identity

Source · BCE/KBO

DR MUYLLE-NUCLEAIRE GENEESKUNDE & DR REYNDERS -KLINISCHE BIOLOGIE is a Private limited company incorporated in 2010. Its main activity is: General medical practice activities. Its registered office is in Maldegem.

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0828.298.539
Incorporation: 05/08/2010
Legal form: Private limited company
Registered office: Oude Staatsbaan 156
9991 Maldegem · FlandreSee on map
Contributed capital: 6 200,00 €
Latest accounts: 31/12/2024

Activities (NACE)

86210General medical practice activities· main 86210General medical practice activities 72109Research and experimental development on natural sciences and engineering 72190Other research and experimental development on natural sciences and engineering

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA

Financials

Source · NBB, 14 filings

Trend over 14 financial years

	2024		2023		2022		2021		2020
Income statement
Gross margin	401 k €	+16.8%	343,3 k €	+51.7%	226,3 k €	-44.6%	408,7 k €	+228%	124,6 k €
EBITDA	365,9 k €	+7.8%	339,3 k €	+52.3%	222,8 k €	-42.5%	387,7 k €	+335%	89,1 k €
Operating result	294,2 k €	+7.5%	273,8 k €	+61.9%	169,1 k €	-47.9%	324,8 k €	+1309%	23,1 k €
Net result	192,2 k €	+7.9%	178,1 k €	+63.5%	108,9 k €	-48.1%	209,7 k €	+2848%	7,1 k €
Balance sheet
Equity	1 M €	+23.2%	828,3 k €	+22.3%	677,3 k €	+10.5%	612,8 k €	+52.0%	403,1 k €
Total assets	1,8 M €	+8.5%	1,7 M €	+8.3%	1,6 M €	-0.5%	1,6 M €	+40.7%	1,1 M €
Cash	117,3 k €	-62.6%	313,6 k €	-24.8%	417,2 k €	-4.6%	437,5 k €	+153%	173,1 k €
Debts	804,1 k €	-5.7%	852,9 k €	-2.5%	874,7 k €	-7.6%	946,4 k €	+34.2%	705,4 k €
Other
Workforce	–		–		–		–		–

Valuation

Indicative valuation

As an indication, this company is worth

between 1 M€ and 2,5 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2024

2 active · 1 ended

Active mandates

Director	Mandates in this company	Period
Kristoff Muylle	DirectorManagerended
Marijke Reynders	DirectorManagerended

Ended mandates

Director	Mandates in this company	Period
Ludo Muylle	Manager

Full financial information

Source · NBB

	2024	2023	2022	2021	2020	2019
Type of account	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model	Abridged model
Start of the financial year	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/01/2019
Closing of the financial year	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	25/09/2025	27/09/2024	09/10/2023	26/09/2022	28/10/2021	09/11/2020
General meeting	07/06/2025	01/06/2024	03/06/2023	04/06/2022	05/06/2021	06/06/2020
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 14 filings

Model	Closing	General meeting	Filed	Language	Document
Abridged model	31/12/2024	07/06/2025	25/09/2025	Dutch	PDF
Abridged model	31/12/2023	01/06/2024	27/09/2024	Dutch	PDF
Abridged model	31/12/2022	03/06/2023	09/10/2023	Dutch	PDF
Abridged model	31/12/2021	04/06/2022	26/09/2022	Dutch	PDF
Abridged model	31/12/2020	05/06/2021	28/10/2021	Dutch	PDF
Abridged model	31/12/2019	06/06/2020	09/11/2020	Dutch	PDF
Abridged model	31/12/2018	01/06/2019	30/09/2019	Dutch	PDF
Abridged model	31/12/2017	02/06/2018	29/10/2018	Dutch	PDF
Abridged model	31/12/2016	03/06/2017	25/09/2017	Dutch	PDF
Abridged model	31/12/2015	04/06/2016	27/10/2016	Dutch	PDF
Abridged model	31/12/2014	06/06/2015	30/09/2015	Dutch	PDF
Abridged model	31/12/2013	07/06/2014	10/09/2014	Dutch	PDF
Abridged model	31/12/2012	01/06/2013	20/09/2013	Dutch	PDF
Abridged model	31/12/2011	02/06/2012	26/09/2012	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 1 M€ and 2,5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2024

2 active · 1 ended

Active mandates

Director	Mandates in this company	Period
Kristoff Muylle	DirectorManagerended
Marijke Reynders	DirectorManagerended

Ended mandates

Director	Mandates in this company	Period
Ludo Muylle	Manager

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates27/08/2020
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - ONTSLAGEN - BENOEMINGEN
PDF
Mandates22/12/2014
ONTSLAGEN - BENOEMINGEN
PDF
Registered office22/09/2010
MAATSCHAPPELIJKE ZETEL
PDF
Other16/08/2010
RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings14 filings

20102011201220132014201520162017201820192020202120222023202420252026

DR MUYLLE-NUCLEAIRE GENEESKUNDE & DR REYNDERS -KLINISCHE BIOLOGIE

Oude Staatsbaan 156, 9991 Adegem

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Oude Staatsbaan 156, 9991 AdegemCurrent	accounts 2021 → 2024	Accounts 2024 · 2025-00517748

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
DR MUYLLE-NUCLEAIRE GENEESKUNDE & DR REYNDERS -KLINISCHE BIOLOGIECurrent	accounts 2021 → 2024	Accounts 2024 · 2025-00517748

Events

2024
Annual accounts 2024192,2 k €↑
2023
Annual accounts 2023178,1 k €↑
2022
Annual accounts 2022108,9 k €↓
2021
Annual accounts 2021209,7 k €↑
2020
Annual accounts 20207,1 k €↑
2019
Annual accounts 20192,9 k €↓
2018
Annual accounts 201833,1 k €↑
2017
Annual accounts 201727 k €↓
2016
Annual accounts 201644,5 k €↓
2015
Annual accounts 2015145,9 k €↑
2014
Annual accounts 2014106,5 k €↑
2013
Annual accounts 201395,1 k €↑
2012
Annual accounts 201221,6 k €↓
2011
Annual accounts 201140,3 k €
05/08/2010
IncorporationPrivate limited company

DR MUYLLE-NUCLEAIRE GENEESKUNDE & DR REYNDERS -KLINISCHE BIOLOGIE

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events